This resource describes how state health departments and other public health organizations can partner with people with HIV and/or who use(d) drugs in programmatic and policy making processes and evaluation.
Resources and Tools
Articles in this supplement focus on the global opioid crisis, including coverage of harm reduction approaches, health justice promotion, and lessons learned.
This publication describes the recent trends of drug overdose deaths in the United States (U.S.) and the benefits of adopting harm reduction approaches.
The COVID-19 pandemic resulted in federal policy changes related to telehealth use that allowed states to maximize access to medications for opioid use disorder (MOUD) through telehealth.
Individuals who have HIV who also use drugs experience increased age-matched morbidity and mortality in comparison with those with HIV who do not use drugs.
This CDC report provides updated data related to HIV prevalence among people who inject drugs, documenting findings that underscore the need for low-barrier access to comprehensive and integrated needs-based syringe service programs for necessary prevention and
Transgender people and communities, including nonbinary people, have specific needs within harm reduction programs.
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
This document provides a quick overview of the federal discretionary funding programs that support essential aspects of the nation’s HIV response.
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.